Sertoli M R, Brunetti I, Ardizzoni A, Falcone A, Guarneri D, Boccardo F, Martorana G, Curotto A, Sicignano A, Rosso R
Department of Medical Oncology, National Institute for Cancer Research, Italy.
Am J Clin Oncol. 1989 Feb;12(1):43-5. doi: 10.1097/00000421-198902000-00010.
Twenty consecutive metastatic renal cell carcinoma patients were treated with a combination of recombinant alpha-2a interferon (18 X 10(6) U three times weekly) and vinblastine (0.1 mg/kg every 3 weeks). Two patients (10% response rate; 95% confidence limits 1.23-31.7%) achieved partial response and 11 (55%) stable disease. Toxicity was significant but always acceptable: most frequently, patients complained of fever and flu-like symptoms (18 of 19 patients), fatigue (18 of 19 patients), worsening in performance status (15 of 19 patients), and anorexia (15 of 19). The combination of recombinant alpha-2a interferon and vinblastine is active in renal cell carcinoma.
20例连续的转移性肾细胞癌患者接受了重组α-2a干扰素（每周3次，每次18×10⁶U）和长春碱（每3周0.1mg/kg）联合治疗。2例患者获得部分缓解（缓解率10%；95%置信区间1.23 - 31.7%），11例（55%）病情稳定。毒性显著但均可耐受：最常见的是，患者出现发热和流感样症状（19例患者中的18例）、疲劳（19例患者中的18例）、体能状态恶化（19例患者中的15例）以及厌食（19例患者中的15例）。重组α-2a干扰素和长春碱联合治疗对肾细胞癌有活性。
